Endocannabinoid Mental Health

Fluid lipid patterns distinguish schizophrenia groups in machine learning…

Identification of fluid endocannabinoid and sphingolipid biomarkers in schizophrenia. A machine learning approach toward clinical value.

Molecular psychiatry • • Highly Relevant
🤖

AI Summary

The study asked whether endocannabinoids and sphingolipids measured in cerebrospinal fluid (CSF) and serum could help distinguish people with schizophrenia from healthy volunteers. Researchers compared matched biofluid samples from antipsychotic-naïve patients (49), treated patients (56), and healthy volunteers (51), using machine learning to identify patterns. The models distinguished the groups with reported AUCs of 0.87–0.94 in CSF and 0.87–0.90 in serum; these results indicate potential for biomarker research, not a validated diagnostic test.

Among the findings, anandamide was the top CSF feature for antipsychotic-naïve patients and was significantly elevated versus healthy volunteers. The analysis also highlighted sphingolipids with a d18:2 backbone in both biofluids, while treatment groups showed different ceramide patterns. These are associations in the measured samples; the abstract cannot establish that the lipid changes cause schizophrenia or that the markers will work in clinical care. This is an abstract-based summary, and the abstract does not report external validation of the models.

💡 Key Findings

1
Machine-learning models distinguished schizophrenia groups from healthy volunteers, with reported AUCs of 0.87–0.94 in CSF and 0.87–0.90 in serum.
High
85%
2
Anandamide was the top CSF feature in antipsychotic-naïve patients and was significantly elevated compared with healthy volunteers (q = 0.010).
High
90%
3
Sphingolipids with a d18:2 backbone were elevated in both CSF and serum of antipsychotic-naïve patients (q < 0.05), suggesting they may warrant study as peripheral markers.
High
85%
4
Ceramide patterns differed in treated patients: C16–C18 species were elevated and species longer than C24 were reduced; the abstract suggests these patterns may reflect antipsychotic metabolic effects.
High
80%

📄 Original Abstract

Schizophrenia (SCZ) diagnosis relies on subjective clinical evaluation, with symptoms often overlapping between psychiatric conditions, hindering early intervention, and creating an urgent need for objective, accessible biomarkers. Lipids, especially endocannabinoid system (ECS) and sphingolipid metabolism members, are promising candidates given their implication in SCZ pathogenesis and measurability in accessible biofluids, with minimally invasive procedures. Our study conducted the first comprehensive crossover of endocannabinoids (eCBs) and sphingolipids in matched cerebrospinal fluid (CSF) and serum samples from antipsychotic-naïve SCZ patients (SCZnaïve, n = 49), antipsychotic-treated patients (SCZtreat, n = 56), and healthy volunteers (HVs, n = 51). The machine learning Integrated Disease Explanation and Risk Scoring (IDEARS) platform was applied to eCBs, N-acylethanolamines, ceramides, and sphingomyelins quantified using liquid chromatography-tandem mass spectrometry, identifying key discriminatory features across biofluids and conditions (CSF AUC: SCZnaïve = 0.87, SCZtreat = 0.94; serum AUC: SCZnaïve = 0.87, SCZtreat = 0.90). Anandamide emerged as the top CSF feature in SCZnaïve patients, showing significantly elevated levels (q = 0.010) compared to HVs. Notably, though not statistically significant under conventional statistics, IDEARS identified anandamide as a top ten serum feature. Additionally, elevated sphingadiene backbone (d18:2) sphingolipids were conserved between the CSF and serum of SCZnaïve (q < 0.05), highlighting their potential as peripheral surrogate markers. Treatment-specific ceramide patterns were also evident, with elevated C16-C18 and reduced long-chain (>C24) species potentially reflecting antipsychotic metabolic effects. Our results support the involvement of the ECS and sphingolipid imbalances in SCZ, highlighting the potential of machine learning for novel biomarker discovery, including stratification across biofluids, and therapeutic monitoring toward more objective psychiatric care.

Related reading

Related Research

Similar Studies

More Endocannabinoid research papers you might find interesting.

Thumbnail for research paper: Mouse study finds tea extract eased G-CSF-related pain, not mobilization
Research
Yesterday

Mouse study finds tea extract eased G-CSF-related pain, not mobilization

Pain Endocannabinoid
Read Summary of Mouse study finds tea extract eased G-CSF-related pain, not mobilization
Thumbnail for research paper: In a mouse PTSD-like model, β-caryophyllene’s effects depended on CB2
Research
2 days ago

In a mouse PTSD-like model, β-caryophyllene’s effects depended on CB2

Endocannabinoid Anxiety
Read Summary of In a mouse PTSD-like model, β-caryophyllene’s effects depended on CB2
Thumbnail for research paper: Review maps periosteal receptor changes with age; therapies remain untested
Research
4 days ago

Review maps periosteal receptor changes with age; therapies remain untested

Endocannabinoid
Read Summary of Review maps periosteal receptor changes with age; therapies remain untested
View all Endocannabinoid research

Explore More Research

Stay informed about the latest cannabis science.

Browse All Papers Education Hub

Your stash, decoded.

SeeHigh IQ - Personalized Cannabis Tracking Appapp